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Context:Recent reportshaveproposedthat sporadicor familialgermlineXq26.3microduplications




5.57. Laboratory testing revealedelevated serumprolactin (185g/L;normal,18g/L), IGF-1 (745g/L;
normal, 64–369g/L), and fastingGH 35.0g/L.Magnetic resonance imagingdemonstrated ahomog-
enous bulky pituitary gland (18  15  13 mm) without obvious adenoma. A pituitary biopsy showed
hyperplastic pituitary tissuewithenlarged cordsofGHandprolactin cells. GermlinePRKAR1A,MEN1,AIP,
DICER1,CDKN1B,andsomaticGNASmutationswerenegative.Medicalmanagementwaschallenginguntil
institution of continuous sc infusion of short-acting octreotide combined with sc pegvisomant and oral
cabergoline. The patient remains well controlledwithminimal side effects 7 years after presentation. His
phenotype suggested XLAG, but his peripheral leukocyte-, saliva-, and buccal cell-derived DNA tested
negative formicroduplication in Xq26.3 orGPR101. However, DNA isolated from the pituitary tissue and
forearm skin showed duplicated dosage of GPR101, suggesting that he is mosaic for this genetic
abnormality.
Conclusions: Our patient is the first to be described with somatic microduplication leading to typical
XLAG phenotype. This patient demonstrates that a negative test for Xq26.3 microduplication or
GPR101 duplication on peripheral blood DNA does not exclude the diagnosis of XLAG because it can
result from amosaic mutation affecting the pituitary. (J Clin EndocrinolMetab 101: 1927–1930, 2016)
X-linked acrogigantism (XLAG) is a recently describedclinical syndrome of early-onset gigantismwith typ-
ical onset in the first few months of life and more often
affecting females (1–3). The disease is associated with mi-
croduplications at Xq26.3 involving the GPR101 gene,
which encodes a G protein-coupled orphan receptor.
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Most of the patients present with a GH and prolactin
(PRL)-secreting pituitary adenoma or less commonly GH
and PRL cell hyperplasia. The vast majority of the previ-
ously described patients required extensive anterior pitu-
itary resection or radiotherapy, resulting in hypopituitar-
ism to control exuberant hormone secretion and growth
velocity, because medical management with somatostatin
analogs has not been sufficient (3).
Case Report and Methods
A4-year and 8-month-oldCaucasian boy presented to the
Montreal Children’s Hospital with rapid growth over the
preceding 2 years. Born at term with a weight of 4.7 kg
(95th percentile), he had grown steadily along the 90th
percentile for lengthup to24months of age andwas above
the median for weight and head circumference. He had
undergone a tonsillectomy and adenoidectomy at the age
of 3 years and 10 months. He complained of intermittent
headaches over the preceding 8 months, was otherwise
asymptomatic, and took no medications. His family his-
torywas unremarkable for any endocrinopathies; hismid-
parental height was 174.5 cm. On examination, he ap-
peared older than his stated age, was prepubertal, and had
coarse facial features, which had developed over the pre-
vious 3 years. His height was 129.7 cm (Z4.89), and
his weight was 35.5 kg (Z  5.57) (WHO Growth
Charts for Canada; Ref. 4) (Figure 1A).
Figure 1. A, Growth chart before and after surgical and medical interventions. Treatment strategies are indicated as follows: arrow, diagnosis and
surgery; DA, dopamine agonist (initially bromocriptine then followed by cabergoline); SSA, somatostatin analog (initially Sandostatin LAR and
Somatuline Autogel, then continuous sc infusion [cSSA] administered at 120–320 g/d dose); and PG, pegvisomant dose, 30–105 mg/wk. B,
Growth velocity in centimeters per year (left y-axis, circles) and IGF-1 concentrations (right y-axis, triangles; fold above 95% upper reference limit
for age). C—F, Magnetic resonance imaging of the pituitary gland, coronal (C) and sagittal (D) view before surgery, and 5 weeks (E) and 24
months (F) after surgery. G and H, Histological examination of the pituitary tissue demonstrates normal architecture of the gland with preservation
of the reticulin network but markedly enlarged cell cords, suggesting diffuse hyperplasia: hematoxylin-eosin staining, 10 (G); and Gömöri’s
reticulin stain, 10 (H). I and J, The gland shows an increase in GH-positive (immunoperoxidase, 10; I) and PRL-positive cells (immunoperoxidase,
10; J).
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Laboratory investigations revealed elevated serumcon-
centrations of PRL (185 g/L; normal, 18 g/L [8043
pmol/L; normal, 788 pmol/L]; Access II; Beckman
Coulter), IGF-1 (74.5g/L;normal for age, 6.4–36.9g/L
[9.78 nmol/L, 0.8–4.8]; Immulite), and a fastingGHof
35.0 g/L (Access II; Beckman Coulter) (Figure 1B). GH
suppressed only to 29.0 g/L after standard oral glucose
load (normal, 1.0). His clinical and biochemical diag-
nosis was pituitary gigantism with hyperprolactinemia.
Magnetic resonance imaging demonstrated a homoge-
neous sellar mass measuring 18 15 13 mmwith mild
suprasellar extension without optic chiasm or cavernous
sinus invasion (Figure 1, C andD). Surgical debulkingwas
performed via transfrontal craniotomy. Histological ex-
amination of the tissue confirmed the absence of adenoma
and demonstrated a hyperplastic pituitary with enlarged
cords of GH and PRL cells (Figure 1, G–J). Cells with
ultrastructural features resemblingmammosomatotrophs
were also identified. Genetic analysis was negative for
germline AIP, PRKAR1A, DICER1, MEN1, and
CDKN1B mutations and for GNAS mutations in both
leukocyte and pituitary tissue-derived DNA. Plasma
GHRH (Inter Science Institute) levels were normal on two
separate samples. His bone age was 5 years.
Postoperatively, his hormone levels remained elevated;
the hyperplastic tissue re-expanded rapidly in the fossa
(Figure 1, E and F), and his growth continued at an ac-
celerated pace (Figure 1, A and B). His management was
challenging. Dopamine agonists proved unsuccessful in
suppressing GH hypersecretion; bromocriptine was initi-
ated for the first 3 months but was later replaced with
cabergoline (0.25–0.5 mg/wk) to control PRL levels.
Long-acting somatostatin analog therapy induced a slight
drop in GH but not in IGF-1 levels. Because the patient
refusedmonthly injections (initially Sandostatin LAR and
then Somatuline Autogel), after about 9 months, treat-
ment was switched to continuous sc infusion of short-
acting octreotide (5) at doses ranging from120–320g/d.
The combination of somatostatin analog and cabergoline
was insufficient to normalize GH or IGF-1 levels. The
addition of theGH receptor antagonist pegvisomant (30–
105 mg/wk) normalized IGF-1 and induced a plateau in
his growth; the pituitary volume remained stable with this
treatment combination (Figure 1F). Around the age of 7.5
years, the parents wished to reduce the dose of pegviso-
mant and short-acting octreotide therapy to allow con-
trolled growth. They felt that he was destined to be a tall
boy; thereafter his growth followed parallel to the 97th
height percentile (Figure 1A), and his IGF-1 remained
within the normal range.
Currently, at the age of 11 years, he remains well; his
growth velocity is normal. He is on oral cabergoline 125
g thrice weekly, short-acting sc octreotide 222 g/24 h,
and sc pegvisomant 20 mg twice weekly.
After the recent description of germline Xq26.3 micro-
duplication in young children with acrogigantism (1),
likely due to the duplicated GPR101 gene within this re-
gion,we tested the patient’s leukocyte-, saliva-, andbuccal
cell-derived DNA using a comparative genomic hybrid-
ization array (BlueGnome CytoChip ISCA 8 60k v2.0;
Illumina) and copy number variation droplet digital PCR
for GPR101 (Taqman assays Hs01818174_cn and
Hs01730605_cn; Life Technologies) without evidence of
Xq26.3 microduplications or GPR101 duplication, al-
though his clinical phenotype was identical to the previ-
ously published patients. We therefore tested DNA iso-
lated from the hyperplastic pituitary tissue and found
duplicated dosage ofGPR101 (Figure 2). DNA extracted
from a forearm skin biopsy also showed the microdupli-
cation, suggesting that he is mosaic for this mutation.
Ethics approval was granted from the Montreal Chil-
dren’s Hospital Research Ethics Board. Informed consent
was obtained for all genetic analyses from the parents of
this boy and for publication of this case report.
Discussion
XLAG often manifests in the first year of life and is more
prevalent in girls. Unlike our case, all previously reported
patients have had either sporadic or familial germline
Xq26.3 microduplications allowing a definitive diagnosis
on leukocyte-derived DNA. Because our case presented
with a typical phenotype, we tested the pituitary tissue
sample, and this showedGPR101microduplication. One
of the four different genomicDNAsampleswe tested from
various tissues also showedGPR101duplication, suggest-
Figure 2. GPR101 copy number as measured with copy number
variation droplet digital PCR (assay id Hs01818174_cn, Life
Technologies), showing two copies of GPR101 for normal female
control, one copy for normal male control, one copy for the patient’s
blood-derived DNA, and two copies for the patient’s pituitary tissue-
derived DNA. Vertical bars show 95% Poisson confidence limits.
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ing that this patient has somatic mosaicism as a result of
a postzygotic mutation. No cases of somatic mosaicism
have been described previously in patients with XLAG
syndrome.
Treatment of XLAG is challenging. Previously de-
scribed cases treated with surgery followed by medical
treatment and/or radiotherapy have often developed hy-
popituitarism and central diabetes insipidus (1–3, 6).
Management of our patient with cabergoline, continuous
sc infusion of short-acting somatostatin analog, and
pegvisomant proved successful in controlling growth
without hypopituitarism or other significant side effects.
Conclusion
This is the first report on a patient with documented so-
maticGPR101 duplication leading to XLAG. The case is
instructive because it: 1) demonstrates that a negative ge-
netic test for Xq26.3 microduplication orGPR101 dupli-
cation on peripheral blood DNA does not exclude the
diagnosis of XLAG because it can result from a somatic
mutation affecting the pituitary and possibly other tissues
as a result of somatic mosaicism; and 2) proposes an ef-
fective combination and route of medical treatment for
this condition that can be acceptable for young children.
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